Cardiol Therapeutics Inc. Expected to Earn Q1 2024 Earnings of ($0.06) Per Share (NASDAQ:CRDL)

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a note issued to investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.43 EPS.

Cardiol Therapeutics Trading Up 4.5 %

CRDL opened at $1.84 on Wednesday. The business has a fifty day moving average price of $1.68 and a 200 day moving average price of $1.20. The stock has a market capitalization of $125.64 million, a price-to-earnings ratio of -5.58 and a beta of 0.95. Cardiol Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.36 and a quick ratio of 4.36.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cardiol Therapeutics stock. Tejara Capital Ltd raised its holdings in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 29.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 645,457 shares of the company’s stock after acquiring an additional 148,396 shares during the quarter. Tejara Capital Ltd owned approximately 1.00% of Cardiol Therapeutics worth $578,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.